Breakthrough sleep apnea medication AD109 shows promising results in phase 3 trials, potentially helping 30 million Americans with the condition.

Sustained vitamin D deficiency (VDD) is independently associated with an increased risk of obstructive sleep apnea (OSA), ...

Assessing mean apnea-hypopnea duration (MAD) in patients with OSA yields hypoxemia and symptom burden data not provided by the AHI or ODI.

Sunrise Group, a pioneer in medical device innovation and sleep care, today announced a new peer-reviewed study in Nature Communications Medicine. Sunrise developed the only home sleep test with ...

It could be a game-changer for the millions of Americans who suffer from sleep apnea. A new first-of-its-kind pill could ...

Credit: Getty Images Obstructive sleep apnea may significantly increase the risk for coronary artery disease, atrial fibrillation, cerebrovascular accident, and congestive heart failure. Obstructive ...

ORLANDO -- Tirzepatide (Zepbound) improved symptoms of moderate-to-severe obstructive sleep apnea (OSA) in people with obesity, regardless of positive airway pressure (PAP) use, the phase III SURMOUNT ...

Sleep apnea is a debilitating disease that many sufferers don’t even realize they have. Those afflicted with the condition ...

DONGGUAN, GUANGDONG, CHINA, January 15, 2026 /EINPresswire.com/ -- As global healthcare evolves towards proactive, ...

--Eli Lilly and Company announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection for the treatment of moderate-to-severe obstructive sleep apnea in ...

The global sleep apnea implants market is projected to expand at a compound annual growth rate (CAGR) of approximately 10% ...

Please provide your email address to receive an email when new articles are posted on . Known/suspected obstructive sleep apnea increased dementia risk for midlife men and women, researchers found. At ...